Overview

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Status:
Active, not recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Akeso